BWM
CADL icon

Baystate Wealth Management’s Candel Therapeutics CADL Stock Holding History

Baystate Wealth Management’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$113K Sell
76,910
-20,400
-21% -$19.8K 0.01% 258
2023
Q3 		$89.5K Sell
97,310
-3,230
-3% -$3.73K 0.01% 265
2023
Q2 		$127K Sell
100,540
-5,314
-5% -$7.85K 0.01% 227
2023
Q1 		$143K Buy
+105,854
New +$206K 0.01% 211

Other funds holding CADL

NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Baystate Wealth Management's CADL Position: Q4 2023 in Review

Baystate Wealth Management reduced its Candel Therapeutics (CADL) stake by 21% in Q4 2023, selling an estimated $19.8K and leaving 76,910 shares worth $113K. The position accounts for 0.01% of the portfolio, ranked #258.

Baystate Wealth Management first reported a position in CADL in Q1 2023 and has held it in 4 quarters since. The position peaked at $143K in Q1 2023. 22 funds tracked by Wall St. Rank hold CADL as of Q4 2023.

  • Baystate Wealth Management held 76,910 shares of Candel Therapeutics worth $113K as of Q4 2023.
  • Baystate Wealth Management sold 20,400 Candel Therapeutics shares in Q4 2023, an estimated $19.8K.
  • Candel Therapeutics made up 0.01% of Baystate Wealth Management's portfolio in Q4 2023, its #258 holding.
  • Baystate Wealth Management first reported a position in Candel Therapeutics in Q1 2023 and has held it in 4 quarters since.
  • Baystate Wealth Management's Candel Therapeutics position peaked at $143K in Q1 2023.
  • 22 funds tracked by Wall St. Rank held Candel Therapeutics as of Q4 2023.

Based on Baystate Wealth Management's 13F filing for Q4 2023, filed 29 Jan 2024.